Nirsevimab and Hospitalization for RSV Bronchiolitis
- Zein Assad; Anne-Sophie Romain; Camille Aupiais; Mickaël Shum; Cécile Schrimpf; Mathie Lorrot
Access Resources
About
This study looks at how well nirsevimab, a monoclonal antibody, works in preventing hospitalizations for RSV bronchiolitis in infants under 12 months. Conducted across multiple centers, it compares infants hospitalized with RSV to those visiting hospitals for other reasons. Results show that nirsevimab reduces the risk of hospitalization by 83% and is also effective against severe cases needing critical care or ventilatory support. The findings suggest that nirsevimab can significantly lower the chances of serious RSV-related illness in young children.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.